bay1747846
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Apr 17, 2019 (NCT06125366)
Timeline
Indications
Mechanism of action
- Unspecified targetContrast agent
contrast agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05915026 | Phase 3 | Aug 16, 2023 | Bayer |
| NCT05915702 | Phase 3 | Jul 24, 2023 | Bayer |
| NCT05915728 | Phase 3 | Jul 24, 2023 | Bayer |
| NCT05061979 | Phase 1 | Oct 12, 2021 | Bayer |
| NCT06135181 | Phase 1 | Aug 26, 2020 | Bayer |
| NCT04307186 | Phase 2 | Jun 30, 2020 | Bayer |
| NCT06125366 | Phase 1 | Apr 17, 2019 | Bayer |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 7 | 7 | 3 | 2019 |
1 organizations
Page 1 / 1